# A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

> **NCT03316131** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 36 (actual)

## Conditions studied

- Asymptomatic Hyperuricemia

## Interventions

- **DRUG:** Verinurad
- **DRUG:** Febuxostat
- **DRUG:** Dapagliflozin
- **OTHER:** Dapagliflozin matched placebo

## Key facts

- **NCT ID:** NCT03316131
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-25
- **Primary completion:** 2018-07-19
- **Final completion:** 2018-07-19
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316131, "A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03316131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*